Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 8/20 | 0.34 |
| ▸ | PRKACA | P17612 | 2/20 | 0.33 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.32 |
| ▸ | TLR4 | O00206 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25835148 | 1.00 | PYGB (0.36) | PYGBADORA1ACHEPRKACAAMDHD2 | |
| SCHEMBL21138017 | 0.86 | PYGB (0.38) | PYGBADORA1ACHEPRKACAAMDHD2 | |
| SCHEMBL21058398 | 0.86 | PYGB (0.38) | PYGBADORA1ACHEPRKACAAMDHD2 | |
| SCHEMBL21137932 | 0.80 | PYGB (0.39) | PYGBAMDHD2TLR4KDM4ELMNA | |
| SCHEMBL25835074 | 0.80 | PYGB (0.39) | PYGBAMDHD2TLR4KDM4ELMNA | |
| SCHEMBL23104926 | 0.80 | PYGB (0.39) | PYGBAMDHD2TLR4KDM4ELMNA | |
| SCHEMBL21137933 | 0.80 | PYGB (0.39) | PYGBAMDHD2TLR4KDM4ELMNA | |
| SCHEMBL21138298 | 0.78 | PYGB (0.53) | PYGBTLR4KDM4ELMNACYP2D6 | |
| SCHEMBL21138012 | 0.78 | PYGB (0.53) | PYGBTLR4KDM4ELMNACYP2D6 | |
| SCHEMBL21058338 | 0.78 | MEN1 (0.36) | PYGBTLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718636-B2 | Glucosamine derivatives for the prevention or treatment of joint disorders | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718636-B2 | Glucosamine derivatives for the prevention or treatment of joint disorders | OGT, UGGT1, GLA | PYGB 760/4885ADORA1 902/4885ACHE 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.